Actavis Promethazine Codeine Cough Syrup Discontinued

Actavis Promethazine Codeine Cough Syrup Discontinued, Actavis, a pharmaceutical company known for its Promethazine with Codeine cough syrup, ceased production of the product in 2014 due to increasing misuse and public health concerns. The syrup, which combines an antihistamine (promethazine) and an opioid (codeine), was originally prescribed for severe coughs and respiratory issues. However, it gained notoriety as a recreational drug, often mixed with soda or candy to create a concoction known as “lean” or “sizzurp.” This trend was popularized by several hip-hop artists, including Justin Bieber and Soulja Boy, leading to widespread abuse and glamorization of the product .

In response to the product’s association with unlawful and dangerous use, Actavis made the unprecedented decision to halt all production and sales of its Promethazine Codeine syrup. A company spokesperson stated that the media attention had glamorized the misuse of the product, which contradicted its intended medical purpose .

The discontinuation led to a surge in demand on the black market, with reports of individuals offering large sums to acquire remaining stock. For instance, a rapper reportedly offered $100,000 to purchase all available Actavis syrup following the announcement .

The misuse of codeine-based cough syrups has been a global concern. In India, authorities have taken steps to phase out such medications due to their potential for abuse. The Indian government has banned several fixed-dose combination (FDC) drugs containing codeine, citing a lack of therapeutic justification and the risk of misuse . This move has impacted major pharmaceutical companies, including Pfizer and Abbott, which had to comply with the ban on their codeine-based cough syrups .

The discontinuation of Actavis’s Promethazine Codeine syrup highlights the challenges faced by pharmaceutical companies and regulators in balancing the therapeutic benefits of medications with their potential for abuse. It underscores the importance of vigilant monitoring and regulation to prevent the misuse of prescription drugs.